Medrone 100mg tablets

Valsts: Lielbritānija

Valoda: angļu

Klimata pārmaiņas: MHRA (Medicines & Healthcare Products Regulatory Agency)

Aktīvā sastāvdaļa:

Methylprednisolone

Pieejams no:

DE Pharmaceuticals

ATĶ kods:

H02AB04

SNN (starptautisko nepatentēto nosaukumu):

Methylprednisolone

Deva:

100mg

Zāļu forma:

Oral tablet

Ievadīšanas:

Oral

Klase:

No Controlled Drug Status

Receptes veids:

Valid as a prescribable product

Produktu pārskats:

BNF: 06030200

Lietošanas instrukcija

PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
MEDRONE® 100MGTABLETS
Methylprednisolone
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU.
•
Keep this leaflet. You may need to read it again.
•
If you have any further questions, ask your doctor or
pharmacist.
•
This medicine has been prescribed for you only. Do not pass
it on to others. It may harm them even if their signs of illness
are the same as yours.
•
If you get any side effects, talk to your doctor or pharmacist.
This includes any possible side effects not listed in this
leaflet. See section 4.
The name of your medicine is Medrone 100mg Tablets but will be
referred to as Medrone throughout the remainder of the leaflet.
WHAT IS IN THIS LEAFLET
1. WHAT MEDRONE IS AND WHAT IT IS USED FOR
2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE MEDRONE
3. HOW TO TAKE MEDRONE
4. POSSIBLE SIDE EFFECTS
5. HOW TO STORE MEDRONE
6. CONTENTS OF THE PACK AND OTHER INFORMATION
1. WHAT MEDRONE IS AND WHAT IT IS USED FOR
This medicine contains methylprednisolone, which belongs to a
group of medicines called steroids. Their full name is
corticosteroids. Corticosteroids are produced naturally in your
body and are important for many body functions.
Boosting your body with extra corticosteroid such as Medrone can
help following surgery (e.g. organ transplants), injuries or other
stressful conditions. These include inflammatory or allergic
conditions affecting the:
•
BRAIN (e.g. tuberculous meningitis)
•
BOWEL and GUT (e.g. Crohn’s disease and ulcerative colitis)
•
BLOOD OR BLOOD VESSELS (e.g. leukaemia or arteritis,
inflammation of the arteries)
•
JOINTS (e.g. rheumatic fever)
•
LUNGS (e.g. asthma, tuberculosis)
•
MUSCLE (e.g. dermatomyositis and polymyositis)
•
SKIN (e.g. pemphigus vulgaris, an auto-immune disorder in
which the body’s immune system is overactive causing the
skin to blister)
Medrone may be prescribed to treat conditions other than those
listed above.
You must talk to a doctor i

Produkta apraksts

OBJECT 1
MEDRONE 100MG TABLETS
Summary of Product Characteristics Updated 25-Apr-2019 | Pfizer
Limited
•
1. Name of the medicinal product
•
2. Qualitative and quantitative composition
•
3. Pharmaceutical form
•
4. Clinical particulars
•
4.1 Therapeutic indications
•
4.2 Posology and method of administration
•
4.3 Contraindications
•
4.4 Special warnings and precautions for use
•
4.5 Interaction with other medicinal products and other forms of
interaction
•
4.6 Fertility, pregnancy and lactation
•
4.7 Effects on ability to drive and use machines
•
4.8 Undesirable effects
•
4.9 Overdose
•
5. Pharmacological properties
•
5.1 Pharmacodynamic properties
•
5.2 Pharmacokinetic properties
•
5.3 Preclinical safety data
•
6. Pharmaceutical particulars
•
6.1 List of excipients
•
6.2 Incompatibilities
•
6.3 Shelf life
•
6.4 Special precautions for storage
•
6.5 Nature and contents of container
•
6.6 Special precautions for disposal and other handling
•
7. Marketing authorisation holder
•
8. Marketing authorisation number(s)
•
9. Date of first authorisation/renewal of the authorisation
•
10. Date of revision of the text
1. Name of the medicinal product
Medrone Tablets 100 mg
2. Qualitative and quantitative composition
Each Medrone Tablet contains 100 mg methylprednisolone.
For the full list of excipients, see section 6.1
3. Pharmaceutical form
Tablet
4. Clinical particulars
4.1 Therapeutic indications
Medrone is a potent corticosteroid with an anti-inflammatory activity
at least five times that of
hydrocortisone. An enhanced separation of glucocorticoid and
mineralocorticoid effect results in a reduced
incidence of sodium and water retention.
Medrone is indicated for conditions requiring glucocorticoid activity
such as:-
1. Collagen diseases/arteritis
Systemic lupus erythematosus
Systemic dermatomyositis (polymyositis)
Rheumatic fever with severe carditis
Giant cell arteritis/polymyalgia rheumatica
2. Dermatological diseases
Pemphigus vulgaris
3. Allergic states
Bronchia